Abstract
The selective monoamine oxidase (MAO) B inhibitor (-)deprenyl failed to produce any greater benefit than placebo in a limited double-blind trial conducted in depressive patients. Its relative freedom from the so-called cheese effect was confirmed, however, in drug-treated patients challenged IV with tyramine. There is evidence to suggest that this cheese effect, a facilitated tyramine-induced hypertensive response, is pharmacologically distinct from MAO inhibition proper. Thus, it is conceivable that its central counterpart, an enhanced noradrenaline release due to the access of traces of tyramine to the CNS, is a prerequisite for any therapeutic benifit obtainable with the MAO-inhibitory drugs in general.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975) The potentiation of the antiakinetic effect after l-dopa treatment by an inhibitor of MAO B, deprenyl. J Neural Transm 36:303–326
Blackwell B, Marley E, Price J, Taylor D (1967) Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry 113:349–365
Coppen A, Shaw DM, Farrell JP (1963) Potentiation of the anti-depressive effect of a monoamine oxidase inhibitor by tryptophan. Lancet I:79–81
Donnelly CH, Murphy DL (1977) Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase. Biochem Pharmacol 26:853–858
Elsworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Phuapradit P, Shaw KM, Stern GM, Kumar P (1978) Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the cheese effect. Psychopharmacology 57:33–38
Everett GM (1974) Effect of 5-hydroxytryptophan on brain levels of dopamine, norepinephrine, and serotonin in mice. In: Costa E, Gessa GL, Sandler M (eds) Serotonin: New vistas. Histochemistry and pharmacology. Raven, New York, pp 261–262
Ghose K, Turner P, Coppen A (1975) Intravenous tyramine pressor response in depression. Lancet I:1317–1318
Glassman AH, Platman SR (1969) Potentiation of a monoamine oxidase inhibitor by tryptophan. J Psychiatr Res 7:83–88
Glover V, Elsworth JD, Sandler M (1980) Dopamine oxidation and its inhibition by (-)deprenyl in man. J Neural Transm (Suppl) 16:163–172
Glover V, Sandler M, Owen F, Riley GJ (1977) Dopamine is a monoamine oxidase B substrate in man. Nature 265:80–81
Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62
Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase. Biochem Pharmacol 17:1285–1297
Joshi VG (1976) Isoniazid (INH) in the treatment of depressive syndrome: A pilot trial. Dis Nerv Syst 37:100–111
Joshi VG, Hazidas RM, Dubey E, Nagesh RP (1980) A controlled clinical trial of isoniazid in the treatment of depressive syndrome. Paper presented at the Annual Conference of the Research Society, GMC and J. J. Group of Hospitals, Bombay, India
Knoll J (1976) Analysis of the pharmacological effects of selective monoamine oxidase inhibitors. In: Wolstenholme GEW, Knight J (eds) Monoamine oxidase and its inhibition. Elsevier, Amsterdam, pp 135–161
Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. In: Costa E, Sandler M (eds) Monoamine oxidases: New vistas. Raven, New York, pp 393–408
Lee KY, Beilin JL, Vandongen R (1979) Severe hypertension after ingestion of an appetite suppressant (phenylpropanolamine) with indomethacin. Lancet 1:41110–1111
Lees AJ, Shaw KM, Kohout LJ, Stern GM, Elsworth JD, Sandler M, Youdim MBH (1977) Deprenyl in Parkinson's disease. Lancet II:791–795
Lejonc JL, Gusmini D, Brochard P (1979) Isoniazid and reaction to cheese. Ann Intern Med 91:793
Lipper S, Murphy DL, Slater S, Buchsbaum MS (1979) Comparative behavioural effects of clorgyline and pargyline in man: A preliminary evaluation. Psychopharmacology 62:123–128
Mann J, Gershon S (1980) l-Deprenyl: A selective monoamine oxidase type B inhibitor in endogenous depression. Life Sci 26:877–882
Mendlewicz J, Youdim MBH (1978) Anti-depressant potentiation of 5-hydroxytryptophan by l-deprenyl, a MAO type B inhibitor. J Neural Transm 43:279–286
Mulgirigama LD, Pare CMB, Turner P, Wadsworth J, Witts DJ (1977) Clinical response in depressed patients in relation to plasma levels of tricyclic antidepressants and tyramine pressor response. Postgrad Med J 53:155–159
Pare CMB (1963) Potentiation of monoamine oxidase inhibitors by tryptophan. Lancet II:527–528
Pare CMB (1977) Monoamine oxidase inhibitors: A personal account. In: Burrows D (ed) Handbook of studies on depression. Excerpta Medica, Amsterdam, pp 195–215
Pare CMB, Sandler M (1959) A clinical and biochemical study of a trial of iproniazid in the treatment of depression. J Neurol Neurosurg Psychiatry 22:247–251
Pare CMB, Sandler M, Stern G (1978) Clinical usefulness of deprenyl: A new MAOI. In: Abstracts Eleventh CINP Congress, Vienna. p 286
Pickar D, Cohen RM, Jamerson DC, Murphy DL (1979a) Selective MAOA and MAOB inhibition and intravenous tyramine pressor sensitivity. In: Eighteenth Annual Meeting of the American College of Neuropsychopharmacology, San Juan
Pickar D, Cohen RM, Murphy DL, Fried D (1979b) Tyramine infusions in bipolar illness: Behavioural effects and longitudinal changes in pressor sensitivity. Am J Psychiatry 136:1460–1463
Reynolds GP, Elsworth JD, Blau K, Sandler M, Lees AJ, Stern GM (1978) Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 6:542–544
Robinson DS, Lovenberg W, Keiser G, Sjoerdsma A (1968) Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo. Biochem Pharmacol 17:109–119
Salzer HM, Lurie ML (1953) Anxiety and depressive states treated with isonicotinyl hydrazide (isoniazid). Arch Neurol Psychiatry 70:317–324
Sandler M, Glover V, Ashford A, Esmail A (1980) The inhibition of tyramine oxidation and the tyramine hypertensive response (cheese effect) may be independent phenomena. J Neural Transm 48:241–247
Singer TP, von Korff RW, Murphy DL (eds) (1979) Monoamine oxidase: Structure, function and altered functions. Academic, New York
Smith CK, Durack DT (1978) Isoniazid and reaction to cheese. Ann Intern Med 88:520–521
Squires RF (1972) Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: A comparison of eight mammalian species. In: Costa E, Sandler M (eds) Monoamine oxidases: New vistas. Raven, New York, pp 355–370
Swash M, Moffett AM, Scott DF (1975) Tyramine activates the EEG in epileptic patients. Nature 258:749
Tringer L, Haits G, Varga E (1971) The effect of (-)phenyl-isopropylmethyl-propinylamine HCl in depressions. In: Leszkowsky GP (ed) Soc. Pharmac. Hung. Vth Conf. Hung. Ther. Hungarian Academy of Sciences, Budapest, pp 111–114
Varga E, Tringer L (1967) Clinical trial of a new type of promptly acting psychoenergetic agent (phenyl-isopropylmethyl-propinylamine HCl, E-250). Acta Med Acad Sci Hung 23:289–295
Weil-Malherbe H, Axelrod J, Tomchick R (1959) Blood-brain barrier for adrenaline. Science 129:1226–1227
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mendis, N., Pare, C.M.B., Sandler, M. et al. Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect?. Psychopharmacology 73, 87–90 (1981). https://doi.org/10.1007/BF00431109
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00431109